|
G
|
Atoh8
|
atonal bHLH transcription factor 8
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of ATOH8 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 4:105,818,203...105,850,379
Ensembl chr 4:105,818,203...105,850,379
|
|
G
|
Cidea
|
cell death-inducing DFFA-like effector a
|
multiple interactions
|
ISO
|
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA
|
CTD |
PMID:34323617 |
|
NCBI chr18:63,164,817...63,190,384
Ensembl chr18:63,164,099...63,190,382
|
|
G
|
Cidec
|
cell death-inducing DFFA-like effector c
|
multiple interactions
|
ISO
|
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA
|
CTD |
PMID:34323617 |
|
NCBI chr 4:148,124,924...148,137,806
Ensembl chr 4:148,124,925...148,137,806
|
|
G
|
Col2a1
|
collagen type II alpha 1 chain
|
multiple interactions
|
EXP
|
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]
|
CTD |
PMID:24709313 |
|
NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:130,977,561...131,006,627
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of CYP1B1 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Fam43a
|
family with sequence similarity 43, member A
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of FAM43A mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr11:83,633,165...83,636,313
Ensembl chr11:83,633,154...83,695,297
|
|
G
|
Fut7
|
fucosyltransferase 7
|
decreases expression
|
ISO
|
Pantothenic Acid results in decreased expression of FUT7 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 3:28,635,913...28,640,407
Ensembl chr 3:28,637,107...28,641,388
|
|
G
|
Hmox1
|
heme oxygenase 1
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of HMOX1 mRNA; Pantothenic Acid results in increased expression of HMOX1 protein
|
CTD |
PMID:19397697 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hspb7
|
heat shock protein family B (small) member 7
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of HSPB7 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 5:159,010,759...159,014,245
Ensembl chr 5:159,010,629...159,014,243
|
|
G
|
Id1
|
inhibitor of DNA binding 1
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of ID1 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685
|
|
G
|
Id3
|
inhibitor of DNA binding 3
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of ID3 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856
|
|
G
|
Idh2
|
isocitrate dehydrogenase (NADP(+)) 2
|
increases abundance multiple interactions
|
ISO
|
IDH2 protein mutant form results in increased abundance of Pantothenic Acid Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Pantothenic Acid]
|
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248
|
|
G
|
Il6
|
interleukin 6
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of IL6 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Ins1
|
insulin 1
|
multiple interactions
|
ISO
|
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA
|
CTD |
PMID:34323617 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
G
|
Lepr
|
leptin receptor
|
affects abundance
|
ISO
|
LEPR affects the abundance of Pantothenic Acid
|
CTD |
PMID:20567778 |
|
NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215
|
|
G
|
Marchf2
|
membrane associated ring-CH-type finger 2
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of MARCHF2 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 7:15,183,931...15,209,988
Ensembl chr 7:15,183,925...15,202,002
|
|
G
|
Mtres1
|
mitochondrial transcription rescue factor 1
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of MTRES1 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr20:48,604,479...48,622,364
Ensembl chr20:48,604,372...48,622,014
|
|
G
|
Myb
|
MYB proto-oncogene, transcription factor
|
multiple interactions
|
ISO
|
Pantothenic Acid inhibits the reaction [Valproic Acid results in decreased expression of MYB protein]
|
CTD |
PMID:16112698 |
|
NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:17,759,309...17,792,547
|
|
G
|
Mycn
|
MYCN proto-oncogene, bHLH transcription factor
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of MYCN mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 6:41,446,683...41,452,584
Ensembl chr 6:41,446,684...41,452,508
|
|
G
|
Nhlrc1
|
NHL repeat containing E3 ubiquitin protein ligase 1
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of NHLRC1 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr17:17,880,570...17,883,411
Ensembl chr17:17,880,365...17,883,620
|
|
G
|
Nr4a1
|
nuclear receptor subfamily 4, group A, member 1
|
multiple interactions
|
ISO
|
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA
|
CTD |
PMID:20505214 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041
|
|
G
|
Nrep
|
neuronal regeneration related protein
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of NREP mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,291,219...25,320,742
|
|
G
|
Pim1
|
Pim-1 proto-oncogene, serine/threonine kinase
|
multiple interactions
|
ISO
|
Pantothenic Acid inhibits the reaction [Valproic Acid results in decreased expression of PIM1 protein]
|
CTD |
PMID:16112698 |
|
NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764
|
|
G
|
Pou3f4
|
POU class 3 homeobox 4
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of POU3F4 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr X:79,974,808...79,976,085
Ensembl chr X:79,974,627...79,987,326
|
|
G
|
Ptprcap
|
protein tyrosine phosphatase, receptor type, C-associated protein
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of PTPRCAP mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 1:210,878,593...210,880,752
Ensembl chr 1:210,878,573...210,881,753
|
|
G
|
Sdha
|
succinate dehydrogenase complex flavoprotein subunit A
|
multiple interactions
|
ISO
|
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein
|
CTD |
PMID:34323617 |
|
NCBI chr 1:30,764,553...30,789,523
Ensembl chr 1:30,764,590...30,790,121
|
|
G
|
Slc51b
|
SLC51 subunit beta
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of SLC51B mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109
|
|
G
|
Slc5a6
|
solute carrier family 5 member 6
|
increases transport multiple interactions
|
EXP ISO
|
SLC5A6 results in increased transport of Pantothenic Acid Sodium affects the reaction [SLC5A6 results in increased transport of Pantothenic Acid] Thioctic Acid inhibits the reaction [SLC5A6 results in increased transport of Pantothenic Acid]
|
CTD |
PMID:9516450 PMID:10329687 |
|
NCBI chr 6:31,039,865...31,051,671
Ensembl chr 6:31,040,017...31,051,670
|
|
G
|
Sox2
|
SRY-box transcription factor 2
|
decreases expression
|
ISO
|
Pantothenic Acid results in decreased expression of SOX2 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350
|
|
G
|
Tf
|
transferrin
|
multiple interactions
|
ISO
|
[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA
|
CTD |
PMID:34323617 |
|
NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:112,647,642...112,695,400
|
|
G
|
Tmem18
|
transmembrane protein 18
|
increases expression
|
ISO
|
Pantothenic Acid results in increased expression of TMEM18 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 6:52,934,419...52,941,868
Ensembl chr 6:52,934,419...52,941,866
|
|
G
|
Zfp575
|
zinc finger protein 575
|
decreases expression
|
ISO
|
Pantothenic Acid results in decreased expression of ZNF575 mRNA
|
CTD |
PMID:19397697 |
|
NCBI chr 1:89,302,927...89,305,087
Ensembl chr 1:89,302,904...89,305,187
|
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
decreases activity
|
ISO
|
Nialamide results in decreased activity of CYP1B1 protein
|
CTD |
PMID:33814510 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Slc47a1
|
solute carrier family 47 member 1
|
multiple interactions
|
ISO
|
Nialamide inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
|
CTD |
PMID:22419765 |
|
NCBI chr10:46,533,580...46,590,128
Ensembl chr10:46,533,583...46,587,096
|
|
G
|
Slc47a2
|
solute carrier family 47 member 2
|
multiple interactions
|
ISO
|
Nialamide inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
|
CTD |
PMID:22419765 |
|
NCBI chr10:46,490,262...46,532,954
Ensembl chr10:46,489,831...46,533,425
|
|
|
G
|
Aif1
|
allograft inflammatory factor 1
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of AIF1 protein
|
CTD |
PMID:27397090 |
|
NCBI chr20:3,651,435...3,657,341
Ensembl chr20:3,652,243...3,657,339
|
|
G
|
Aldh1a2
|
aldehyde dehydrogenase 1 family, member A2
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of ALDH1A2 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883
|
|
G
|
Eya1
|
EYA transcriptional coactivator and phosphatase 1
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of EYA1 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614
|
|
G
|
F2
|
coagulation factor II, thrombin
|
decreases activity
|
ISO
|
Dabigatran results in decreased activity of F2 protein
|
CTD |
PMID:17911567 PMID:25138021 |
|
NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246
|
|
G
|
Fga
|
fibrinogen alpha chain
|
multiple interactions
|
ISO
|
Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]
|
CTD |
PMID:25138021 |
|
NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577
|
|
G
|
Fgb
|
fibrinogen beta chain
|
multiple interactions
|
ISO
|
Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]
|
CTD |
PMID:25138021 |
|
NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434
|
|
G
|
Fgf8
|
fibroblast growth factor 8
|
increases expression
|
ISO
|
Dabigatran results in increased expression of FGF8 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605
|
|
G
|
Fgg
|
fibrinogen gamma chain
|
multiple interactions
|
ISO
|
Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]
|
CTD |
PMID:25138021 |
|
NCBI chr 2:170,652,929...170,660,372
Ensembl chr 2:170,652,234...170,661,170
|
|
G
|
Foxc2
|
forkhead box C2
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of FOXC2 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr19:66,094,718...66,097,420
Ensembl chr19:66,094,700...66,153,977
|
|
G
|
Gdnf
|
glial cell derived neurotrophic factor
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of GDNF mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240
|
|
G
|
Gfap
|
glial fibrillary acidic protein
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of GFAP protein
|
CTD |
PMID:27397090 |
|
NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685
|
|
G
|
Hoxb9
|
homeo box B9
|
increases expression
|
ISO
|
Dabigatran results in increased expression of HOXB9 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr10:81,733,857...81,737,363
Ensembl chr10:81,733,658...81,738,872
|
|
G
|
Meox1
|
mesenchyme homeobox 1
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of MEOX1 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr10:87,318,668...87,338,169
Ensembl chr10:87,318,695...87,337,976
|
|
G
|
Mertk
|
MER proto-oncogene, tyrosine kinase
|
increases expression
|
ISO
|
Dabigatran results in increased expression of MERTK mRNA
|
CTD |
PMID:27397090 |
|
NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:136,383,560...136,500,192
|
|
G
|
Neurog2
|
neurogenin 2
|
increases expression
|
ISO
|
Dabigatran results in increased expression of NEUROG2 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 2:218,767,205...218,769,772
Ensembl chr 2:218,765,949...218,769,784
|
|
G
|
Nr4a2
|
nuclear receptor subfamily 4, group A, member 2
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of NR4A2 mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:62,098,743...62,106,769
|
|
G
|
Olig3
|
oligodendrocyte transcription factor 3
|
increases expression
|
ISO
|
Dabigatran results in increased expression of OLIG3 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 1:15,900,881...15,902,953
Ensembl chr 1:15,900,736...15,902,274
|
|
G
|
Pax3
|
paired box 3
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of PAX3 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141
|
|
G
|
Pax6
|
paired box 6
|
increases expression
|
ISO
|
Dabigatran results in increased expression of PAX6 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763
|
|
G
|
Plp1
|
proteolipid protein 1
|
increases expression
|
ISO
|
Dabigatran results in increased expression of PLP1 mRNA
|
CTD |
PMID:27397090 |
|
NCBI chr X:104,933,921...104,993,317
Ensembl chr X:104,975,780...104,993,314
|
|
G
|
Rcor2
|
REST corepressor 2
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of RCOR2 mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 1:213,882,585...213,890,022
Ensembl chr 1:213,878,519...213,890,022
|
|
G
|
Ret
|
ret proto-oncogene
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of RET protein]
|
CTD |
PMID:28585189 |
|
NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556
|
|
G
|
Slc18a2
|
solute carrier family 18 member A2
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of SLC18A2 mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 1:268,399,815...268,435,229
Ensembl chr 1:268,400,016...268,435,231
|
|
G
|
Snca
|
synuclein alpha
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in increased expression of SNCA mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315
|
|
G
|
Tcf15
|
transcription factor 15
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of TCF15 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 3:161,099,301...161,105,083
Ensembl chr 3:161,099,301...161,105,083
|
|
G
|
Th
|
tyrosine hydroxylase
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of TH mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in increased expression of TNF mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Uncx
|
UNC homeobox
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of UNCX mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr12:20,206,604...20,211,125
Ensembl chr12:20,206,609...20,211,125
|
|
|
G
|
Adam1a
|
ADAM metallopeptidase domain 1a
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of ADAM1 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr12:40,674,460...40,680,988
Ensembl chr12:40,676,918...40,684,619
|
|
G
|
Adra1b
|
adrenoceptor alpha 1B
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of ADRA1B mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347
|
|
G
|
Agtpbp1
|
ATP/GTP binding carboxypeptidase 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of AGTPBP1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr17:5,092,108...5,244,414
Ensembl chr17:5,126,146...5,244,420
|
|
G
|
Akr1b1
|
aldo-keto reductase family 1 member B1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of AKR1B1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315
|
|
G
|
Ap2b1
|
adaptor related protein complex 2 subunit beta 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of AP2B1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr10:68,596,925...68,702,547
Ensembl chr10:68,597,093...68,702,539
|
|
G
|
Arap1
|
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of ARAP1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:165,160,701...165,226,219
Ensembl chr 1:165,160,678...165,226,218
|
|
G
|
Arc
|
activity-regulated cytoskeleton-associated protein
|
affects expression
|
EXP
|
Methylphenidate affects the expression of ARC mRNA
|
CTD |
PMID:19222557 |
|
NCBI chr 7:108,444,959...108,448,413
Ensembl chr 7:108,444,692...108,451,220
|
|
G
|
Arih2
|
ariadne RBR E3 ubiquitin protein ligase 2
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of ARIH2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 8:118,175,267...118,234,425
Ensembl chr 8:118,175,267...118,234,284
|
|
G
|
Armc9
|
armadillo repeat containing 9
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of ARMC9 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 9:94,250,492...94,376,589
Ensembl chr 9:94,250,859...94,376,589
|
|
G
|
Atg5
|
autophagy related 5
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of ATG5 mRNA
|
CTD |
PMID:32746681 |
|
NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821
|
|
G
|
B4galt4
|
beta-1,4-galactosyltransferase 4
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of B4GALT4 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr11:75,501,358...75,527,291
Ensembl chr11:75,501,366...75,527,177
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of BAX mRNA
|
CTD |
PMID:32746681 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bbc3
|
Bcl-2 binding component 3
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of BBC3 mRNA
|
CTD |
PMID:32746681 |
|
NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666
|
|
G
|
Bcl9
|
BCL9, transcription coactivator
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of BCL9 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 2:187,449,425...187,475,241
Ensembl chr 2:187,449,425...187,475,241
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
affects expression decreases expression multiple interactions
|
EXP ISO
|
Methylphenidate affects the expression of BDNF mRNA Methylphenidate results in decreased expression of BDNF mRNA [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]
|
CTD |
PMID:19222557 PMID:22470460 PMID:24394491 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Becn1
|
beclin 1
|
increases expression
|
EXP ISO
|
Methylphenidate results in increased expression of BECN1 mRNA
|
CTD |
PMID:32746681 PMID:32748667 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
G
|
C2
|
complement C2
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of C2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr20:3,944,722...3,975,006
Ensembl chr20:3,955,776...3,981,740
|
|
G
|
Cald1
|
caldesmon 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of CALD1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 4:64,232,906...64,414,085
Ensembl chr 4:64,233,171...64,414,085
|
|
G
|
Casp3
|
caspase 3
|
increases expression multiple interactions
|
EXP ISO
|
Methylphenidate results in increased expression of CASP3 mRNA Methylphenidate results in increased expression of and results in increased activity of CASP3 protein
|
CTD |
PMID:32746681 PMID:32748667 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of CASP8 mRNA
|
CTD |
PMID:32746681 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
ISO
|
Methylphenidate results in increased expression of and results in increased activity of CASP9 protein
|
CTD |
PMID:32748667 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cat
|
catalase
|
increases activity decreases activity
|
EXP ISO
|
Methylphenidate results in increased activity of CAT protein Methylphenidate results in decreased activity of CAT protein
|
CTD |
PMID:32746681 PMID:32748667 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cbr3
|
carbonyl reductase 3
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of CBR3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558
|
|
G
|
Ccdc166
|
coiled-coil domain containing 166
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of CCDC166 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 7:109,574,271...109,576,074
Ensembl chr 7:109,574,273...109,576,074
|
|
G
|
Ccdc91
|
coiled-coil domain containing 91
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of CCDC91 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 4:182,132,931...182,304,948
Ensembl chr 4:182,132,942...182,304,948
|
|
G
|
Cdk5r1
|
cyclin-dependent kinase 5 regulatory subunit 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of CDK5R1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr10:65,981,692...65,985,831
Ensembl chr10:65,978,911...65,989,272
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of CDKN1A mRNA
|
CTD |
PMID:32746681 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Ces1d
|
carboxylesterase 1D
|
multiple interactions increases hydrolysis increases metabolic processing
|
ISO
|
[CES1 protein results in increased hydrolysis of Methylphenidate] which results in increased chemical synthesis of ritalinic acid; Aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; CES1 gene mutant form results in decreased metabolism of and results in increased abundance of Methylphenidate; Fluoxetine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; Perphenazine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; Thioridazine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate] aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate] CES1 protein results in increased metabolism of Methylphenidate
|
CTD |
PMID:15082749 PMID:18485328 PMID:20097249 PMID:25445008 |
|
NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449
|
|
G
|
Chd2
|
chromodomain helicase DNA binding protein 2
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of CHD2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:136,597,993...136,726,874
Ensembl chr 1:136,599,900...136,710,335
|
|
G
|
Chga
|
chromogranin A
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of CHGA mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:127,460,854...127,472,237
|
|
G
|
Chid1
|
chitinase domain containing 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of CHID1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:206,024,059...206,059,259
Ensembl chr 1:205,998,801...206,059,227
|
|
G
|
Chrna6
|
cholinergic receptor nicotinic alpha 6 subunit
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of CHRNA6 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr16:71,400,615...71,407,315
Ensembl chr16:71,400,615...71,407,315
|
|
G
|
Chst8
|
carbohydrate sulfotransferase 8
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of CHST8 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:96,431,144...96,572,880
Ensembl chr 1:96,431,145...96,572,880
|
|
G
|
Clpx
|
caseinolytic mitochondrial matrix peptidase chaperone subunit X
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of CLPX mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 8:74,700,602...74,740,244
Ensembl chr 8:74,700,662...74,744,762
|
|
G
|
Cnnm1
|
cyclin and CBS domain divalent metal cation transport mediator 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of CNNM1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:252,245,377...252,304,205
Ensembl chr 1:252,245,623...252,304,205
|
|
G
|
Cnot6l
|
CCR4-NOT transcription complex, subunit 6-like
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of CNOT6L mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr14:13,714,475...13,806,481
Ensembl chr14:13,714,475...13,806,481
|
|
G
|
Cnr1
|
cannabinoid receptor 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of CNR1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252
|
|
G
|
Cntn3
|
contactin 3
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of CNTN3 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 4:136,397,575...136,770,765
Ensembl chr 4:136,398,572...136,770,717
|
|
G
|
Cntn4
|
contactin 4
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of CNTN4 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 4:140,180,696...141,177,771
Ensembl chr 4:140,596,284...141,177,766
|
|
G
|
Comtd1
|
catechol-O-methyltransferase domain containing 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of COMTD1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr15:2,509,121...2,512,232
Ensembl chr15:2,509,032...2,512,232
|
|
G
|
Creb1
|
cAMP responsive element binding protein 1
|
multiple interactions decreases expression
|
EXP
|
[Fluoxetine co-treated with Methylphenidate] results in increased expression of CREB1 mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of CREB1 protein Methylphenidate results in decreased expression of CREB1 mRNA
|
CTD |
PMID:21753012 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339
|
|
G
|
D2hgdh
|
D-2-hydroxyglutarate dehydrogenase
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of D2HGDH mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 9:101,796,287...101,815,727
Ensembl chr 9:101,797,895...101,815,727
|
|
G
|
Dab2
|
DAB adaptor protein 2
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of DAB2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 2:57,241,947...57,294,893
Ensembl chr 2:57,242,064...57,294,888
|
|
G
|
Dapk3
|
death-associated protein kinase 3
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of DAPK3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 7:9,174,903...9,183,272
Ensembl chr 7:9,174,904...9,183,272
|
|
G
|
Dhx35
|
DEAH-box helicase 35
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of DHX35 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 3:167,869,971...167,927,300
Ensembl chr 3:167,870,055...167,927,300
|
|
G
|
Drd1
|
dopamine receptor D1
|
multiple interactions
|
EXP
|
[SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to Methylphenidate
|
CTD |
PMID:11454915 |
|
NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,545,111...10,567,166
|
|
G
|
Drd2
|
dopamine receptor D2
|
multiple interactions decreases expression affects expression
|
EXP ISO
|
[Raclopride binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Methylphenidate Methylphenidate results in decreased expression of DRD2 mRNA Methylphenidate affects the expression of DRD2 protein
|
CTD |
PMID:11454915 PMID:17599397 PMID:22470460 PMID:33647392 |
|
NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339
|
|
G
|
Drd4
|
dopamine receptor D4
|
affects response to substance
|
ISO
|
DRD4 promoter mutant form affects the susceptibility to Methylphenidate
|
CTD |
PMID:17023870 |
|
NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:205,826,049...205,830,458
|
|
G
|
Egr1
|
early growth response 1
|
multiple interactions increases expression
|
EXP
|
[Fluoxetine co-treated with Methylphenidate] results in increased expression of EGR1 mRNA; Fluoxetine promotes the reaction [Methylphenidate results in increased expression of EGR1 mRNA]; Methylphenidate promotes the reaction [Amphetamine results in increased expression of EGR1 mRNA]; SCH 23390 inhibits the reaction [Methylphenidate results in increased expression of EGR1 mRNA]
|
CTD |
PMID:16549270 PMID:19931852 PMID:20020108 PMID:21753012 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843
|
|
G
|
Entpd5
|
ectonucleoside triphosphate diphosphohydrolase 5
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of ENTPD5 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 6:109,750,210...109,786,376
Ensembl chr 6:109,753,204...109,786,495
|
|
G
|
Epb41l1
|
erythrocyte membrane protein band 4.1-like 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of EPB41L1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 3:165,389,295...165,512,821
Ensembl chr 3:165,389,293...165,510,498
|
|
G
|
Epha10
|
EPH receptor A10
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of EPHA10 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 5:142,424,260...142,460,305
Ensembl chr 5:142,424,296...142,460,305
|
|
G
|
Exog
|
exo/endonuclease G
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of EXOG mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 8:128,062,688...128,082,529
Ensembl chr 8:128,059,126...128,083,460
|
|
G
|
Fank1
|
fibronectin type III and ankyrin repeat domains 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of FANK1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:198,007,496...198,114,790
Ensembl chr 1:198,007,547...198,115,561
|
|
G
|
Fcgr2b
|
Fc gamma receptor 2B
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of FCGR2B mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr13:85,725,897...85,740,517
Ensembl chr13:85,725,897...85,740,517
|
|
G
|
Fgf14
|
fibroblast growth factor 14
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of FGF14 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr15:107,442,800...108,086,486
Ensembl chr15:107,451,634...108,085,808
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
[Methylphenidate co-treated with SLC6A3 protein] results in increased expression of FOS protein; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] Methylphenidate results in increased expression of FOS mRNA [Fluoxetine co-treated with Methylphenidate] results in increased expression of FOS mRNA; Fluoxetine promotes the reaction [Methylphenidate results in increased expression of FOS mRNA] Methylphenidate results in increased expression of FOS protein Methylphenidate results in decreased expression of FOS protein SLC6A3 protein affects the reaction [Methylphenidate results in increased expression of FOS protein] Methylphenidate results in increased expression of FOS mRNA; Methylphenidate results in increased expression of FOS protein
|
CTD |
PMID:12112414 PMID:12699766 PMID:15916815 PMID:19931852 PMID:21753012 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Fosb
|
FosB proto-oncogene, AP-1 transcription factor subunit
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of FOSB protein
|
CTD |
PMID:15916815 |
|
NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477
|
|
G
|
Galnt10
|
polypeptide N-acetylgalactosaminyltransferase 10
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of GALNT10 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr10:42,321,691...42,468,087
Ensembl chr10:42,322,161...42,468,087
|
|
G
|
Gch1
|
GTP cyclohydrolase 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of GCH1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr15:22,884,006...22,917,412
Ensembl chr15:22,884,006...22,917,412
|
|
G
|
Gdnf
|
glial cell derived neurotrophic factor
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of GDNF mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240
|
|
G
|
Ghdc
|
GH3 domain containing
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of GHDC mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr10:86,193,920...86,198,141
Ensembl chr10:86,193,929...86,198,141
|
|
G
|
Gjb6
|
gap junction protein, beta 6
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of GJB6 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr15:35,400,147...35,410,649
Ensembl chr15:35,398,770...35,410,849
|
|
G
|
Grik2
|
glutamate ionotropic receptor kainate type subunit 2
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of GRIK2 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr20:53,717,564...54,415,283
Ensembl chr20:53,716,090...54,415,202
|
|
G
|
Grik3
|
glutamate ionotropic receptor kainate type subunit 3
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of GRIK3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 5:143,052,442...143,268,873
Ensembl chr 5:143,052,442...143,268,873
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
decreases activity
|
ISO
|
Methylphenidate results in decreased activity of GSR protein
|
CTD |
PMID:32748667 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Gucy2c
|
guanylate cyclase 2C
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of GUCY2C mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 4:171,299,715...171,380,296
Ensembl chr 4:171,299,740...171,380,296
|
|
G
|
Hbp1
|
HMG-box transcription factor 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of HBP1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 6:54,257,118...54,283,373
Ensembl chr 6:54,256,864...54,283,366
|
|
G
|
Hmgb1
|
high mobility group box 1
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of HMGB1 mRNA
|
CTD |
PMID:32746681 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327 Ensembl chr12:39,039,050...39,041,327
|
|
G
|
Hmmr
|
hyaluronan-mediated motility receptor
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of HMMR mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr10:25,635,249...25,665,389
Ensembl chr10:25,635,915...25,665,390
|
|
G
|
Hmox1
|
heme oxygenase 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of HMOX1 protein
|
CTD |
PMID:32748667 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Homer1
|
homer scaffold protein 1
|
increases expression multiple interactions
|
EXP
|
Methylphenidate results in increased expression of HOMER1 mRNA SCH 23390 inhibits the reaction [Methylphenidate results in increased expression of HOMER1 mRNA]
|
CTD |
PMID:16549270 PMID:17105903 |
|
NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:26,278,105...26,381,657
|
|
G
|
Hspb6
|
heat shock protein family B (small) member 6
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of HSPB6 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:94,934,372...94,936,516
Ensembl chr 1:94,933,543...94,936,512
|
|
G
|
Htr1a
|
5-hydroxytryptamine receptor 1A
|
decreases expression
|
EXP
|
Methylphenidate decreases expression of Htr1a mRNA in the nucleus accumbens
|
RGD |
PMID:30594665 |
RGD:405866343 |
NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:38,427,083...38,540,760
|
|
G
|
Htr7
|
5-hydroxytryptamine receptor 7
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of HTR7 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 1:243,049,064...243,173,636
Ensembl chr 1:243,049,081...243,173,230
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of IL1B mRNA
|
CTD |
PMID:32746681 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
increases expression
|
ISO EXP
|
Methylphenidate results in increased expression of IL6 mRNA
|
CTD |
PMID:22470460 PMID:32746681 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Ip6k1
|
inositol hexakisphosphate kinase 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of IP6K1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 8:117,594,177...117,613,266
Ensembl chr 8:117,594,317...117,613,274
|
|
G
|
Itga6
|
integrin subunit alpha 6
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of ITGA6 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 3:77,012,168...77,097,076
Ensembl chr 3:77,017,766...77,097,076
|
|
G
|
Itpr2
|
inositol 1,4,5-trisphosphate receptor, type 2
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of ITPR2 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 4:180,759,325...181,165,361
Ensembl chr 4:180,760,442...181,164,763
|
|
G
|
Jak1
|
Janus kinase 1
|
increases phosphorylation
|
ISO
|
Methylphenidate results in increased phosphorylation of JAK1 protein
|
CTD |
PMID:32748667 |
|
NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758
|
|
G
|
Jak3
|
Janus kinase 3
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of JAK3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr16:18,418,807...18,432,515
Ensembl chr16:18,420,415...18,433,222
|
|
G
|
Kcnk15
|
potassium two pore domain channel subfamily K member 15
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of KCNK15 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 3:172,934,659...172,940,877
Ensembl chr 3:172,934,544...172,940,877
|
|
G
|
Kcnk3
|
potassium two pore domain channel subfamily K member 3
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of KCNK3 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 6:31,483,129...31,519,061
Ensembl chr 6:31,483,140...31,519,061
|
|
G
|
Kifc3
|
kinesin family member C3
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of KIFC3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr19:9,831,159...9,926,405
Ensembl chr19:9,831,159...9,926,405
|
|
G
|
Lad1
|
ladinin 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of LAD1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr13:49,801,347...49,815,709
Ensembl chr13:49,800,472...49,815,709
|
|
G
|
Lama3
|
laminin subunit alpha 3
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of LAMA3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr18:3,797,898...4,033,021
Ensembl chr18:3,797,939...4,026,449
|
|
G
|
Lamb1
|
laminin subunit beta 1
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of LAMB1 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 6:53,562,849...53,630,118
Ensembl chr 6:53,563,073...53,630,760
|
|
G
|
Lamp2
|
lysosomal-associated membrane protein 2
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of LAMP2 mRNA
|
CTD |
PMID:32746681 |
|
NCBI chr X:122,038,734...122,087,745
Ensembl chr X:121,922,187...122,087,675
|
|
G
|
Large1
|
LARGE xylosyl- and glucuronyltransferase 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of LARGE1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr19:11,609,004...12,057,174
Ensembl chr19:11,609,004...12,054,707
|
|
G
|
Lasp1
|
LIM and SH3 protein 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of LASP1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr10:83,290,820...83,331,989
Ensembl chr10:83,290,865...83,331,988
|
|
G
|
Lgals3bp
|
galectin 3 binding protein
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of LGALS3BP mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr10:104,118,510...104,127,848
Ensembl chr10:104,118,510...104,127,848
|
|
G
|
Lhfpl5
|
LHFPL tetraspan subfamily member 5
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of LHFPL5 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr20:6,634,058...6,644,264
Ensembl chr20:6,633,979...6,644,657
|
|
G
|
Lrrc27
|
leucine rich repeat containing 27
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of LRRC27 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:203,433,463...203,464,683
Ensembl chr 1:203,434,355...203,464,676
|
|
G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
decreases expression increases expression
|
ISO EXP
|
Methylphenidate results in decreased expression of MAP1LC3B mRNA Methylphenidate results in increased expression of MAP1LC3B protein Methylphenidate results in increased expression of MAP1LC3B mRNA
|
CTD |
PMID:22470460 PMID:32746681 PMID:32748667 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358 Ensembl chr16:66,574,407...66,584,358
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
decreases expression multiple interactions
|
EXP
|
Methylphenidate results in decreased expression of MAPK1 mRNA [Fluoxetine co-treated with Methylphenidate] results in increased expression of MAPK1 mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MAPK1 protein
|
CTD |
PMID:21753012 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of MAPK8 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mlc1
|
modulator of VRAC current 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of MLC1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 7:121,926,356...121,949,484
Ensembl chr 7:121,926,356...121,946,698
|
|
G
|
Mmp14
|
matrix metallopeptidase 14
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of MMP14 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893
|
|
G
|
Morn2
|
MORN repeat containing 2
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of MORN2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 6:20,471,036...20,477,520
|
|
G
|
Mpp3
|
MAGUK p55 scaffold protein 3
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of MPP3 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr10:87,445,905...87,475,461
Ensembl chr10:87,445,905...87,474,811
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
multiple interactions increases expression affects expression
|
EXP
|
[Fluoxetine co-treated with Methylphenidate] results in increased expression of MTOR mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MTOR protein Methylphenidate results in increased expression of MTOR mRNA Methylphenidate affects the expression of MTOR mRNA
|
CTD |
PMID:21753012 PMID:32746681 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
G
|
Mvp
|
major vault protein
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of MVP mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:191,025,259...191,052,866
Ensembl chr 1:191,025,268...191,052,873
|
|
G
|
Nabp1
|
nucleic acid binding protein 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of NABP1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 9:57,570,326...57,625,926
Ensembl chr 9:57,618,505...57,626,052
|
|
G
|
Nacad
|
NAC alpha domain containing
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of NACAD mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr14:85,679,215...85,688,742
Ensembl chr14:85,679,215...85,688,147
|
|
G
|
Ncor2
|
nuclear receptor co-repressor 2
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of NCOR2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr12:37,127,736...37,289,612
Ensembl chr12:37,127,686...37,289,612
|
|
G
|
Neto2
|
neuropilin and tolloid like 2
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of NETO2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr19:37,517,518...37,588,961
Ensembl chr19:37,517,587...37,591,413
|
|
G
|
Nol3
|
nucleolar protein 3
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of NOL3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr19:50,066,493...50,068,175
Ensembl chr19:50,063,986...50,068,722
|
|
G
|
Nox4
|
NADPH oxidase 4
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of NOX4 protein
|
CTD |
PMID:32748667 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483
|
|
G
|
Nsun4
|
NOP2/Sun RNA methyltransferase 4
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of NSUN4 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 5:134,749,024...134,773,630
Ensembl chr 5:134,749,024...134,775,401
|
|
G
|
Ntrk2
|
neurotrophic receptor tyrosine kinase 2
|
multiple interactions
|
ISO
|
[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]
|
CTD |
PMID:24394491 |
|
NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,564,570...5,874,628
|
|
G
|
Parp3
|
poly (ADP-ribose) polymerase family, member 3
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of PARP3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 8:115,989,721...115,995,822
Ensembl chr 8:115,987,176...115,995,472
|
|
G
|
Pear1
|
platelet endothelial aggregation receptor 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of PEAR1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 2:175,504,184...175,531,969
Ensembl chr 2:175,505,550...175,525,322
|
|
G
|
Peds1
|
plasmanylethanolamine desaturase 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of PEDS1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 3:176,769,111...176,788,278
|
|
G
|
Pisd
|
phosphatidylserine decarboxylase
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of PISD mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr14:82,166,401...82,215,479
Ensembl chr14:82,166,412...82,215,913
|
|
G
|
Pkn1
|
protein kinase N1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of PKN1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr19:41,346,855...41,374,832
Ensembl chr19:41,346,860...41,378,395
|
|
G
|
Pnma8b
|
PNMA family member 8B
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of PNMA8B mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:86,749,840...86,754,605
Ensembl chr 1:86,748,610...86,767,756
|
|
G
|
Prkg2
|
protein kinase cGMP-dependent 2
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of PRKG2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr14:10,864,020...10,972,617
Ensembl chr14:10,864,186...10,972,614
|
|
G
|
Prlr
|
prolactin receptor
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of PRLR mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 2:60,861,391...61,051,883
Ensembl chr 2:60,861,658...61,051,882
|
|
G
|
Prpf39
|
pre-mRNA processing factor 39
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of PRPF39 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 6:88,825,227...88,851,342
Ensembl chr 6:88,825,243...88,851,341
|
|
G
|
Ptdss2
|
phosphatidylserine synthase 2
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of PTDSS2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:205,671,024...205,695,556
Ensembl chr 1:205,671,041...205,695,553
|
|
G
|
Ptpn21
|
protein tyrosine phosphatase, non-receptor type 21
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of PTPN21 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 6:123,662,783...123,727,809
Ensembl chr 6:123,662,783...123,727,809
|
|
G
|
Pus7l
|
pseudouridine synthase 7 like
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of PUS7L mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 7:127,538,785...127,561,936
Ensembl chr 7:127,538,558...127,561,798
|
|
G
|
Rab13
|
RAB13, member RAS oncogene family
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of RAB13 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 2:177,972,535...177,977,679
Ensembl chr 2:177,972,372...177,977,684
|
|
G
|
Rab38
|
RAB38, member RAS oncogene family
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of RAB38 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:151,595,153...151,675,492
Ensembl chr 1:151,595,078...151,675,493
|
|
G
|
Racgap1
|
Rac GTPase-activating protein 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of RACGAP1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 7:132,629,789...132,659,738
Ensembl chr 7:132,620,595...132,659,738
|
|
G
|
Rbfox1
|
RNA binding fox-1 homolog 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of RBFOX1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr10:8,658,809...10,754,648
Ensembl chr10:8,658,809...10,754,706
|
|
G
|
Rcc2
|
regulator of chromosome condensation 2
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of RCC2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 5:158,277,476...158,300,294
Ensembl chr 5:158,277,476...158,300,294
|
|
G
|
Ret
|
ret proto-oncogene
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of RET mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556
|
|
G
|
Rgma
|
repulsive guidance molecule BMP co-receptor a
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of RGMA mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:136,538,782...136,582,763
Ensembl chr 1:136,538,759...136,582,763
|
|
G
|
Rgs20
|
regulator of G-protein signaling 20
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of RGS20 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 5:19,282,249...19,412,122
Ensembl chr 5:19,282,153...19,413,286
|
|
G
|
Rhbdd2
|
rhomboid domain containing 2
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of RHBDD2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr12:26,680,206...26,690,926
Ensembl chr12:26,680,969...26,691,080
|
|
G
|
Sdc3
|
syndecan 3
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of SDC3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 5:148,249,792...148,282,524
Ensembl chr 5:148,271,842...148,280,614
|
|
G
|
Shank2
|
SH3 and multiple ankyrin repeat domains 2
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of SHANK2 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 1:208,575,144...209,020,300
Ensembl chr 1:208,598,772...209,018,736
|
|
G
|
Siae
|
sialic acid acetylesterase
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of SIAE mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 8:45,507,465...45,542,740
Ensembl chr 8:45,507,326...45,542,740
|
|
G
|
Slc10a4
|
solute carrier family 10, member 4
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of SLC10A4 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr14:35,552,170...35,557,884
Ensembl chr14:35,552,170...35,557,884
|
|
G
|
Slc18a2
|
solute carrier family 18 member A2
|
decreases expression decreases activity
|
ISO
|
Methylphenidate results in decreased expression of SLC18A2 mRNA Methylphenidate results in decreased activity of SLC18A2 protein
|
CTD |
PMID:22470460 PMID:33378168 |
|
NCBI chr 1:268,399,815...268,435,229
Ensembl chr 1:268,400,016...268,435,231
|
|
G
|
Slc2a12
|
solute carrier family 2 member 12
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of SLC2A12 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:24,623,558...24,683,577
Ensembl chr 1:24,589,707...24,694,290
|
|
G
|
Slc6a3
|
solute carrier family 6 member 3
|
multiple interactions decreases expression increases response to substance affects response to substance
|
ISO
|
[Methylphenidate co-treated with SLC6A3 protein] results in increased expression of FOS protein; [SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate] which affects the uptake of Dopamine; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] Methylphenidate results in decreased expression of SLC6A3 mRNA Methylphenidate results in decreased expression of SLC6A3 protein SLC6A3 protein results in increased susceptibility to Methylphenidate SLC6A3 protein affects the reaction [Methylphenidate results in increased expression of FOS protein] SLC6A3 3' UTR polymorphism affects the susceptibility to Methylphenidate; SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate
|
CTD |
PMID:12112414 PMID:12699766 PMID:15059031 PMID:16139732 PMID:17234900 PMID:18614672 PMID:19462300 PMID:22470460 PMID:31009648 PMID:33647392 More...
|
|
NCBI chr 1:31,537,990...31,578,962
Ensembl chr 1:31,537,990...31,578,962
|
|
G
|
Snap25
|
synaptosome associated protein 25
|
affects response to substance
|
ISO
|
SNAP25 gene polymorphism affects the susceptibility to Methylphenidate
|
CTD |
PMID:17023870 |
|
NCBI chr 3:144,494,579...144,576,449
Ensembl chr 3:144,494,595...144,576,448
|
|
G
|
Sncaip
|
synuclein, alpha interacting protein
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of SNCAIP mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr18:48,402,164...48,542,246
Ensembl chr18:48,404,531...48,574,002
|
|
G
|
Sncg
|
synuclein, gamma
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of SNCG mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr16:9,706,765...9,712,072
Ensembl chr16:9,706,753...9,712,076
|
|
G
|
Snx22
|
sorting nexin 22
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of SNX22 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 8:75,503,297...75,509,271
Ensembl chr 8:75,504,282...75,507,939
|
|
G
|
Sorcs3
|
sortilin-related VPS10 domain containing receptor 3
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of SORCS3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:257,040,442...257,675,259
Ensembl chr 1:257,040,473...257,675,259
|
|
G
|
Sox11
|
SRY-box transcription factor 11
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of SOX11 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 6:49,736,773...49,738,794
Ensembl chr 6:49,736,304...49,738,691
|
|
G
|
Stat1
|
signal transducer and activator of transcription 1
|
increases phosphorylation
|
ISO
|
Methylphenidate results in increased phosphorylation of STAT1 protein
|
CTD |
PMID:32748667 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346
|
|
G
|
Stat5a
|
signal transducer and activator of transcription 5A
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of STAT5A mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr10:86,285,859...86,310,187
Ensembl chr10:86,285,547...86,310,184
|
|
G
|
Stox2
|
storkhead box 2
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of STOX2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr16:51,580,855...51,819,909
Ensembl chr16:51,580,798...51,815,209
|
|
G
|
Suds3
|
SDS3 homolog, SIN3A corepressor complex component
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of SUDS3 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr12:45,137,964...45,160,413
Ensembl chr12:45,138,400...45,160,411
|
|
G
|
Taar1
|
trace-amine-associated receptor 1
|
multiple interactions
|
ISO
|
Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]
|
CTD |
PMID:17234900 |
|
NCBI chr 1:23,336,978...23,337,976
Ensembl chr 1:23,335,165...23,353,981
|
|
G
|
Tgfb3
|
transforming growth factor, beta 3
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of TGFB3 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:111,435,170...111,456,946
|
|
G
|
Th
|
tyrosine hydroxylase
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of TH mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227
|
|
G
|
Timp2
|
TIMP metallopeptidase inhibitor 2
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of TIMP2 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214
|
|
G
|
Timp3
|
TIMP metallopeptidase inhibitor 3
|
increases expression
|
EXP
|
Methylphenidate results in increased expression of TIMP3 mRNA
|
CTD |
PMID:17105903 |
|
NCBI chr 7:19,408,539...19,459,558
Ensembl chr 7:19,409,631...19,459,547
|
|
G
|
Tmem185b
|
transmembrane protein 185B
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of TMEM185B mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr13:33,200,329...33,203,660
Ensembl chr13:33,198,929...33,204,091
|
|
G
|
Tmem30a
|
transmembrane protein 30A
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of TMEM30A mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 8:89,608,975...89,637,421
Ensembl chr 8:89,608,975...89,633,291
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of TNF mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Traf5
|
TNF receptor-associated factor 5
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of TRAF5 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr13:106,100,921...106,149,724
Ensembl chr13:106,103,291...106,149,707
|
|
G
|
Trim25
|
tripartite motif-containing 25
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of TRIM25 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr10:74,310,024...74,328,473
Ensembl chr10:74,310,022...74,331,716
|
|
G
|
Tspan17
|
tetraspanin 17
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of TSPAN17 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr17:9,824,353...9,831,985
Ensembl chr17:9,823,990...9,831,974
|
|
G
|
Ttf1
|
transcription termination factor 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of TTF1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 3:32,782,544...32,807,202
Ensembl chr 3:32,782,308...32,807,201
|
|
G
|
Twsg1
|
twisted gastrulation BMP signaling modulator 1
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of TWSG1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 9:112,979,972...113,014,315
Ensembl chr 9:112,979,972...113,014,315
|
|
G
|
Ube3d
|
ubiquitin protein ligase E3D
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of UBE3D mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 8:96,125,609...96,293,122
Ensembl chr 8:95,882,167...96,293,078
|
|
G
|
Ubxn10
|
UBX domain protein 10
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of UBXN10 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 5:156,237,041...156,242,877
Ensembl chr 5:156,216,565...156,243,741
|
|
G
|
Uck2
|
uridine-cytidine kinase 2
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of UCK2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr13:81,913,732...81,971,036
Ensembl chr13:81,916,818...81,971,091
|
|
G
|
Vash1
|
vasohibin 1
|
increases expression
|
ISO
|
Methylphenidate results in increased expression of VASH1 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 6:112,060,086...112,076,689
Ensembl chr 6:112,060,086...112,076,689
|
|
G
|
Wars2
|
tryptophanyl tRNA synthetase 2 (mitochondrial)
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of WARS2 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 2:189,150,322...189,233,606
Ensembl chr 2:189,145,371...189,232,970
|
|
G
|
Zfp14
|
ZFP14 zinc finger protein
|
decreases expression
|
ISO
|
Methylphenidate results in decreased expression of ZFP14 mRNA
|
CTD |
PMID:22470460 |
|
NCBI chr 1:94,396,055...94,413,338
Ensembl chr 1:94,396,057...94,413,534
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions decreases activity
|
ISO
|
pilsicainide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] pilsicainide results in decreased activity of ABCB11 protein
|
CTD |
PMID:24014644 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
|
G
|
Aadat
|
aminoadipate aminotransferase
|
decreases activity
|
EXP
|
tiagabine results in decreased activity of AADAT protein
|
CTD |
PMID:16765940 |
|
NCBI chr16:34,520,236...34,566,388
Ensembl chr16:34,520,238...34,566,540
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions increases expression
|
EXP
|
Amino Acids, Peptides, and Proteins inhibits the reaction [tiagabine results in increased expression of ABCB1 protein]
|
CTD |
PMID:18473823 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
increases expression
|
EXP
|
tiagabine results in increased expression of ABCC1 protein
|
CTD |
PMID:18473823 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
increases expression
|
EXP
|
tiagabine results in increased expression of ABCC2 protein
|
CTD |
PMID:18473823 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Cyp19a1
|
cytochrome P450, family 19, subfamily a, polypeptide 1
|
decreases activity
|
ISO
|
tiagabine results in decreased activity of CYP19A1 protein
|
CTD |
PMID:17959350 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917
|
|
G
|
Kyat1
|
kynurenine aminotransferase 1
|
decreases activity
|
EXP
|
tiagabine results in decreased activity of KYAT1 protein
|
CTD |
PMID:16765940 |
|
NCBI chr 3:33,857,407...33,891,153
Ensembl chr 3:33,857,743...33,890,642
|
|
G
|
Slc6a1
|
solute carrier family 6 member 1
|
decreases activity
|
ISO
|
tiagabine results in decreased activity of SLC6A1 protein
|
CTD |
PMID:15788781 |
|
NCBI chr 4:149,004,447...149,037,840
Ensembl chr 4:149,004,635...149,037,839
|
|